Ausgabe Sonderheft 2/2007
Controversies in breast cancer
Inhalt (28 Artikel)
Review
HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
Neil Spector, Wenle Xia, Iman El-Hariry, Yossi Yarden, Sarah Bacus
Short communication
The case for user involvement in research: the research priorities of cancer patients
David NM Wright, Jessica L Corner, Jane B Hopkinson, Claire L Foster
Short communication
A personal viewpoint against the motion that breast cancer patient advocacy groups unfairly distort the cancer budget
Emma L Pennery
Short communication
Is breast cancer advocacy distorting the cancer budget to the disadvantage of other tumours?
Jim Cassidy
Short communication
Why patient recorded outcomes should be mandatory in and outside clinical trials to guide management of patients with metastatic breast cancer
Lesley Fallowfield
Section introduction
Introduction to sessions on Personalising treatment
Mitch Dowsett, William R Miller
Short communication
Short-term presurgical treatment for all?
Mitch Dowsett, Janine Salter, Margaret Hills, Simone Detre, Roger A'Hern, Ian E Smith
Short communication
Adjuvant treatment: the contribution of expression microarrays
Per Eystein Lønning, Ranjan Chrisanthar, Vidar Staalesen, Stian Knappskog, Johan Lillehaug
Short communication
Does presurgical treatment destroy important prognostic information
J Michael Dixon
Short communication
Do classical oestrogen markers predict for clinical response to endocrine therapy?
William R Miller
Short communication
Oestrogen is bad for patients with breast cancer?
V Craig Jordan, Eric A Ariazi, Joan S Lewis-Wambi, Ramona R Swaby, Heather E Cunliffe, Anna T Riegel, Anton Wellstein